Rhenman & Partners Asset Management Ab Alnylam Pharmaceuticals, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 50,350 shares of ALNY stock, worth $12.5 Million. This represents 1.15% of its overall portfolio holdings.

Number of Shares

50,350

Previous 85,500 41.11%

Holding current value

$12.5 Million

Previous $20.8 Million 33.34%

% of portfolio

1.15%

Previous 2.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$233.81 - $287.01 $8.22 Million - $10.1 Million	-35,150 Reduced 41.11%	50,350 $13.9 Million
Q2 2024 Aug 13, 2024	BUY	$143.31 - $247.0 $6.19 Million - $10.7 Million	43,200 Added 102.13%	85,500 $20.8 Million
Q1 2024 May 14, 2024	BUY	$146.51 - $198.2 $703,248 - $951,360	4,800 Added 12.8%	42,300 $6.32 Million
Q4 2023 Feb 13, 2024	SELL	$151.41 - $196.57 $1.14 Million - $1.47 Million	-7,500 Reduced 16.67%	37,500 $7.18 Million
Q3 2023 Nov 13, 2023	SELL	$170.77 - $211.65 $12.6 Million - $15.7 Million	-74,000 Reduced 62.18%	45,000 $7.97 Million
Q3 2023 Nov 09, 2023	BUY	$170.77 - $211.65 $12.6 Million - $15.7 Million	74,000 Added 164.44%	119,000 $21.1 Million
Q2 2023 Aug 11, 2023	SELL	$185.01 - $212.05 $5.74 Million - $6.57 Million	-31,000 Reduced 40.79%	45,000 $8.55 Million
Q1 2023 May 11, 2023	BUY	$182.66 - $235.53 $547,980 - $706,590	3,000 Added 4.11%	76,000 $15.2 Million
Q4 2022 Feb 13, 2023	SELL	$185.53 - $241.31 $371,060 - $482,620	-2,000 Reduced 2.67%	73,000 $17.3 Million
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $6.62 Million - $9.31 Million	-55,000 Reduced 42.31%	75,000 $10.9 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $5.72 Million - $7.83 Million	-45,000 Reduced 25.71%	130,000 $21.2 Million
Q4 2021 Feb 11, 2022	BUY	$159.56 - $209.29 $12 Million - $15.7 Million	75,000 Added 75.0%	175,000 $29.9 Million
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $5.94 Million - $7.27 Million	-35,000 Reduced 25.93%	100,000 $18.9 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $2.96 Million - $4.09 Million	23,300 Added 20.86%	135,000 $19.1 Million
Q4 2020 Jan 19, 2021	BUY	$122.97 - $147.0 $1.44 Million - $1.72 Million	11,700 Added 11.7%	111,700 $14.5 Million
Q3 2020 Oct 13, 2020	BUY	$121.19 - $165.49 $4.59 Million - $6.27 Million	37,905 Added 61.04%	100,000 $14.6 Million
Q2 2020 Jul 16, 2020	SELL	$104.21 - $156.44 $1.87 Million - $2.8 Million	-17,905 Reduced 22.38%	62,095 $9.2 Million
Q1 2020 Apr 16, 2020	BUY	$93.12 - $133.99 $1.8 Million - $2.58 Million	19,285 Added 31.76%	80,000 $8.71 Million
Q4 2019 Jan 17, 2020	SELL	$74.51 - $124.23 $617,315 - $1.03 Million	-8,285 Reduced 12.01%	60,715 $6.99 Million
Q3 2019 Oct 16, 2019	SELL	$70.9 - $87.82 $889,795 - $1.1 Million	-12,550 Reduced 15.39%	69,000 $5.55 Million
Q2 2019 Jul 22, 2019	SELL	$65.86 - $92.79 $658,600 - $927,900	-10,000 Reduced 10.92%	81,550 $5.92 Million
Q1 2019 Apr 11, 2019	SELL	$72.76 - $93.45 $1.46 Million - $1.87 Million	-20,000 Reduced 17.93%	91,550 $8.56 Million
Q4 2018 Feb 05, 2019	SELL	$62.67 - $88.33 $3.79 Million - $5.34 Million	-60,400 Reduced 35.13%	111,550 $8.13 Million
Q3 2018 Oct 03, 2018	BUY	$87.52 - $122.67 $5.07 Million - $7.11 Million	57,983 Added 50.88%	171,950 $15 Million
Q2 2018 Jul 20, 2018	BUY	$88.31 - $107.8 $2.65 Million - $3.23 Million	30,000 Added 35.73%	113,967 $11.2 Million
Q1 2018 Apr 11, 2018	BUY	$115.92 - $148.54 $2.9 Million - $3.71 Million	25,000 Added 42.4%	83,967 $10 Million
Q4 2017 Jan 19, 2018	BUY	$114.49 - $139.98 $1.85 Million - $2.26 Million	16,174 Added 37.8%	58,967 $7.49 Million
Q3 2017 Oct 13, 2017	BUY	$72.53 - $118.27 $3.1 Million - $5.06 Million	42,793	42,793 $5.03 Million

Others Institutions Holding ALNY

# of Institutions

642

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Alnylam Pharmaceuticals, Inc. Transaction History